By Fineline Cube 
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service agreement with Eisai (TYO: 4523), becoming the exclusive promoter of Eisai’s Methycobal (mecobalamin) in Mainland China. This strategic partnership will see Eisai pay Gloria Pharma market promotion service fees as outlined in the agreement.
Agreement Terms
The agreement is valid until March 31, 2026, with an option to extend for an additional two years until March 31, 2028. Eisai’s Methycobal, an originator drug developed and marketed by Eisai’s China unit, is available in a strength of 1ml:0.5mg per vial. It is indicated for the treatment of peripheral neuropathy and megaloblastic anemia caused by vitamin B12 deficiency.
Market Performance
In the first half of 2024, Methycobal generated RMB 110 million (USD 15.2 million) in domestic hospital sales, with Eisai China holding a significant market share of 63.26%. This collaboration aims to further enhance the drug’s market presence in Mainland China.-Fineline Info & Tech